Iovance Biotherapeutics targets significant market expansion, with lung cancer representing a $10B U.S. peak sales ...

A review article led by researchers from the B·ARGO group at the Germans Trias i Pujol Research Institute (IGTP) and from the ...

Renuka Iyer, M.D., will assume the role of CMO at NCCN, focusing on advancing evidence-based cancer care and guideline ...

A review article led by researchers from the B·ARGO group at the Germans Trias i Pujol Research Institute (IGTP) and from the Medical Oncology ...

After difficult chemotherapy, she switched to a regimen of biological drugs targeting a specific gene mutation. The new ...

The patient received trifluridine/tipiracil plus bevacizumab as third-line therapy; is currently on month 4 of treatment.​ ...

A final discussion point is real-world applicability. Although PHAROS presents exceptional PFS, the modest difference between ...

CHICAGO -- First-line treatment with encorafenib (Braftovi) and cetuximab (Erbitux) plus chemotherapy significantly improved survival outcomes compared with standard of care in patients with BRAF ...

LUT014 gel significantly reduces acne-like rashes from anti-EGFR therapies in colorectal cancer patients, improving quality of life. The phase 2 trial showed 70% improvement with high-dose gel, ...

Please provide your email address to receive an email when new articles are posted on . In this video, Michael Cecchini, MD, discusses the significance of results from the phase 3 BREAKWATER trial, ...

Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefited from first-line treatment with the targeted therapies encorafenib and cetuximab plus a mFOLFOX6 chemotherapy ...